Post-castration syndrome: relevance, impact on quality of life, methods of correction
https://doi.org/10.29413/ABS.2024-9.1.11
Abstract
Aspects of modern medicine cover a huge number of diseases, including postcastration syndrome, which occurs as a result of endocrine testicular dysfunction in men. The relevance of this condition is great, since it is caused by many reasons and is the basis for an inferior life in men. The review shows the impact of this disease on the quality of life and the methods for its treatment. When writing this review, we used data on castration methods and its correction based on materials published in the eLibrary and PubMed databases. The search was carried out using the keywords: “castration”, “post-castration syndrome”, “prostate cancer”. With castration, there is a decrease in serum testosterone levels, as androgens stimulate the growth of prostate cancer. Today, hormone therapy is an alternative to castration in the treatment of prostate cancer. Surgical castration is the gold standard; it can suppress tumor cell proliferation and induce tumor apoptosis, but it causes significant impairment of quality of life. The article presents characteristics of medications, indications, contraindications and side effects of hormone therapy. The quality of life of men with testosterone deficiency is clinically associated with the development of metabolic syndrome, manifested by obesity, hepatic steatosis and type 2 diabetes mellitus. Numerous studies by domestic and foreign scientists confirm the effect of castration in men on their body, which increases the risk of stroke, depression, cognitive disorders and Alzheimer’s disease. Thus, despite the significant advances of modern medicine in the treatment of malignant diseases of prostate, post-castration syndrome remains a completely unexplored problem, which indicates the need for further study and the development of effective therapy.
About the Authors
A. M. Ziganshin
Bashkir State Medical University
Russian Federation
Russian Federation
Lenina str. 3, Ufa 450008
M. R. Tagirov
Bashkir State Medical University
Russian Federation
Russian Federation
Lenina str. 3, Ufa 450008
D. O. Baboyan
Bashkir State Medical University
Russian Federation
Russian Federation
Lenina str. 3, Ufa 450008
References
1. Pushkar DY, Govorov AV, Vasilyev AO, Kolontarev KB, Prilepskaya EA, Kovylina MV, et al. Moscow program of early detection and treatment of prostate cancer. Problems of Social Hygiene, Public Health and History of Medicine. 2019; 27(Spec. Iss.): 677-686. (In Russ.). doi: 10.32687/0869-866X-2019-27-si1-677-686
2. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018; 8(12): a030361. doi: 10.1101/cshperspect.a030361
3. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022; 43(6): 1003-1037. doi: 10.1210/endrev/bnac010
4. Agarwal A, Dayal A, Kircher SM, Chen RC, Royce TJ. Analysis of price transparency via National Cancer Institute-designated cancer centers’ chargemasters for prostate cancer radiation therapy. JAMA Oncol. 2020; 6(3): 409-412. doi: 10.1001/jamaoncol.2019.5690
5. Grigorian A, Livingston JK, Schubl SD, Hasjim BJ, Mayers D, Kuncir E, et al. National analysis of testicular and scrotal trauma in the USA. Res Rep Urol. 2018; 10: 51-56. doi: 10.2147/RRU.S172848
6. Bizic MR, Jeftovic M, Pusica S, Stojanovic B, Duisin D, Vujovic S, et al. Gender dysphoria: Bioethical aspects of medical treatment. Biomed Res Int. 2018; 2018: 9652305. doi: 10.1155/2018/9652305
7. Tollinche LE, Walters CB, Radix A, Long M, Galante L, Goldstein ZG, et al. The perioperative care of the transgender patient. Anesth Analg. 2018; 127(2): 359-366. doi: 10.1213/ANE.0000000000003371
8. Salas-Humara C, Sequeira GM, Rossi W, Dhar CP. Gender affirming medical care of transgender youth. Curr Probl Pediatr Adolesc Health Care. 2019; 49(9): 100683. doi: 10.1016/j.cppeds.2019.100683
9. Jacobsen FM, Rudlang TM, Fode M, Østergren PB, Sønksen J, Ohl DA, et al. The impact of testicular torsion on testicular function. World J Mens Health. 2020; 38(3): 298-307. doi: 10.5534/wjmh.190037
10. Shin J, Jeon GW. Comparison of diagnostic and treatment guidelines for undescended testis. Clin Exp Pediatr. 2020; 63(11): 415-421. doi: 10.3345/cep.2019.01438
11. Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C, et al. Risk factors for cryptorchidism. Nat Rev Urol. 2017; 14(9): 534-548. doi: 10.1038/nrurol.2017.90
12. Steele CB, Li J, Huang B, Weir HK. Prostate cancer survival in the United States by race and stage (2001–2009): Findings from the CONCORD-2 study. Cancer. 2017; 123(Suppl 24): 5160- 5177. doi: 10.1002/cncr.31026
13. Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7: F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1
14. Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: A STOPCAP systematic review and meta-analysis. Eur Urol. 2019; 76(1): 115-124. doi: 10.1016/j.eururo.2019.02.003
15. Itty S, Getzenberg RH. How do we define “castration” in men on androgen deprivation therapy? Asian J Androl. 2020; 22(5): 441-446. doi: 10.4103/aja.aja_139_19
16. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-1177. doi: 10.1016/S0140-6736(15)01037-5
17. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial. J Clin Oncol. 2016; 34(18): 2098-2106. doi: 10.1200/JCO.2015.64.9285
18. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castrationresistant prostate cancer. N Engl J Med. 2018; 378(26): 2465-2474. doi: 10.1056/NEJMoa1800536
19. Yecies T, Bandari J, Schneck F, Cannon G. Direction of rotation in testicular torsion and identification of predictors of testicular salvage. Urology. 2018; 114: 163-166. doi: 10.1016/j.urology.2017.11.034
20. Mellick LB, Sinex JE, Gibson RW, Mears K. A systematic review of testicle survival time after a torsion event. Pediatr Emerg Care. 2019; 35(12): 821-825. doi: 10.1097/PEC.0000000000001287
21. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: Further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018; 73(6): 847-855. doi: 10.1016/j.eururo.2018.02.001
22. Tucci M, Leone G, Buttigliero C, Zichi C, Di Stefano RF, Pignataro D, et al. Hormonal treatment and quality of life of prostate cancer patients: New evidence. Minerva Urol Nefrol. 2018; 70(2): 144-151. doi: 10.23736/S0393-2249.17.03066-1
23. Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. Eur Urol. 2019; 75(3): 410-418. doi: 10.1016/j.eururo.2018.09.008
24. Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018; 29(5): 1249-1257. doi: 10.1093/annonc/mdy071
25. Srivatsav A, Balasubramanian A, Butaney M, Thirumavalavan N, McBride JA, Gondokusumo J, et al. Patient attitudes toward testicular prosthesis placement after orchiectomy. Am J Mens Health. 2019; 13(4): 1557988319861019. doi: 10.1177/1557988319861019
26. Anderson E, Pascoe C, Sathianathen N, Katz D, Murphy D, Lawrentschuk N. Subinguinal orchiectomy – A minimally invasive approach to open surgery. BJUI Compass. 2020; 1(5): 160-164. doi: 10.1002/bco2.33
27. Clifford TG, Burg ML, Hu B, Loh-Doyle J, Hugen CM, Cai J, et al. Satisfaction with testicular prosthesis after radical orchiectomy. Urology. 2018; 114: 128-132. doi: 10.1016/j.urology.2017.12.006
28. Baird DC, Meyers GJ, Hu JS. Testicular cancer: Diagnosis and treatment. Am Fam Physician. 2018; 97(4): 261-268.
29. Elenkov A, Giwercman A. Testicular dysfunction among cancer survivors. Endocrinol Metab Clin North Am. 2022; 51(1): 173-186. doi: 10.1016/j.ecl.2021.11.014
30. Leone G, Tucci M, Buttigliero C, Zichi C, Pignataro D, Bironzo P, et al. Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Endocr Relat Cancer. 2018; 25(1): R1-R9. doi: 10.1530/ERC-17-0355
31. Scialpi M, Improta A, Carpini DD, Tonto M, Nicola R, Mancioli F. Biparametric magnetic resonance imaging in the surveillance of testicular tumors following radical orchiectomy. Turk JUrol. 2020; 46(6): 436-441. doi: 10.5152/tud.2020.20353
32. Hana T, Raveendran L, Grober E, Potter E, Blodgett N, Krakowsky Y. Initial clinical experience with simple orchiectomy procedures in the context of transition-related surgeries. Int J Transgend Health. 2020; 21(4): 403-409. doi: 10.1080/26895269.2020.1774030
33. Canner JK, Harfouch O, Kodadek LM, Pelaez D, Coon D, Offodile AC 2nd, et al. Temporal trends in gender-affirming surgery among transgender patients in the United States. JAMA Surg. 2018; 153(7): 609-616. doi: 10.1001/jamasurg.2017.6231
34. Orakwe DE, Tijani KH, Jeje EA, Ogunjimi MA, Rufus WO, Alabi TO. Bilateral subcapsular orchiectomy versus bilateral total orchiectomy: Comparison of the quality of life post-orchiectomy. Niger Postgrad Med J. 2018; 25(1): 43-47. doi: 10.4103/npmj.npmj_169_17
35. Topuz B, Sarıkaya S, Korkmaz C, Baykal B, Kaya E, Ebiloğlu T, et al. Examination of clinical data and semen analysis results of patients undergoing orchiectomy for testicular tumor. Rev Assoc Med Bras (1992). 2021; 67(4): 577-584. doi: 10.1590/1806-9282.20201096
36. Kajitani N, Takahashi J, Honda H, Hamahara J, Ando S. Severe visceral obesity, fatty liver and diabetes after orchiectomy for prostate cancer. Intern Med. 2020; 59(18): 2281-2285. doi: 10.2169/internalmedicine.4653-20
37. Baik M, Jeong JY, Park SJ, Yoo SP, Lee JO, Lee JS, et al. Testosterone deficiency caused by castration increases adiposity in male rats in a tissue-specific and diet-dependent manner. Genes Nutr. 2020; 15(1): 14. doi: 10.1186/s12263-020-00673-1
38. Robert J, Gomes FE, Porter I, Sumner JP. Orbital apex syndrome secondary to an orbital sarcoma in a dog. Can Vet J. 2021; 62(1): 27-31.
39. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019; 37(32): 2974-2986. doi: 10.1200/JCO.19.00799
40. Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers (Basel). 2021; 13(2): 334. doi: 10.3390/cancers13020334
41. Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nat Commun. 2019; 10(1): 207. doi: 10.1038/s41467-018-08170-1
42. McFarland DC, Walsh L, Napolitano S, Morita J, Jaiswal R. Suicide in Patients with cancer: Identifying the risk factors. Oncology (Williston Park). 2019; 33(6): 221-6.
43. Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019; 22(1): 24-38. doi: 10.1038/s41391-018-0079-0
44. Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 2020; 78(3): 347-357. doi: 10.1016/j.eururo.2020.04.061
45. Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021; 16(7): e0255239. doi: 10.1371/journal.pone.0255239
46. Catalona WJ. Prostate cancer screening. Med Clin North Am. 2018; 102(2): 199-214. doi: 10.1016/j.mcna.2017. 11.001
47. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019; 70: 479-499. doi: 10.1146/annurev-med-051517-011947
48. Bandarkar AN, Blask AR. Testicular torsion with preserved flow: Key sonographic features and value-added approach to diagnosis. Pediatr Radiol. 2018; 48(5): 735-744. doi: 10.1007/ s00247-018-4093-0
49. Sindhu II, Noor N, Mansoor R. Choriocarcinoma syndrome: A rare presentation of testicular germ cell tumour. J Pak Med Assoc. 2021; 71(8): 2090-2092. doi: 10.47391/ JPMA.234
Review
For citations:
Ziganshin A.M., Tagirov M.R., Baboyan D.O. Post-castration syndrome: relevance, impact on quality of life, methods of correction. Acta Biomedica Scientifica. 2024;9(1):107-115. (In Russ.) https://doi.org/10.29413/ABS.2024-9.1.11
Views:
699
Email this article 
